Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

ConditionsHead and Neck Squamous Cell Carcinoma Head and Neck Cancer HNSCC Head Cancer Neck

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About this trial

To explore the efficiency and safety of Tislelizumab combinated with carboplatin and polymeric micellar paclitaxel as a new neoadjuvant treatment regimen for resectable HNSCC patients with clinical positive lymph node metastasis

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Carboplatin
Tislelizumab
Polymeric Micellar Paclitaxel
Surgical Resection of Primary +/- Neck Dissection
Post-operative radiation therapy

Treatment groups

85 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Lead sponsor

Source ClinicalTrials.gov